Intervention Protocol

You have free access to this content

Aripiprazole for neuroleptic induced hyperprolactinaemia

  1. Venkata B Kolli1,*,
  2. Durga P Bestha2,
  3. Vishal Madaan3,
  4. Seenaiah Byreddy4

Editorial Group: Cochrane Schizophrenia Group

Published Online: 16 OCT 2013

DOI: 10.1002/14651858.CD010786

How to Cite

Kolli VB, Bestha DP, Madaan V, Byreddy S. Aripiprazole for neuroleptic induced hyperprolactinaemia (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010786. DOI: 10.1002/14651858.CD010786.

Author Information

  1. 1

    Creighton-Nebraska Psychiatry Residency Programme, Psychiatry, Omaha, Nebraska, USA

  2. 2

    Carolinas HealthCare System, Behavioral Health Center, Charlotte, North Carolina, USA

  3. 3

    University of Virginia, Department of Psychiatry & Neurobehavioral Sciences, Virginia, USA

  4. 4

    University of Arizona, Neurology, Tuscon, Arizona, USA

*Venkata B Kolli, Psychiatry, Creighton-Nebraska Psychiatry Residency Programme, 985582 Nebraska Medical Centre, Omaha, Nebraska, 68198-5582, USA.

Publication History

  1. Publication Status: New
  2. Published Online: 16 OCT 2013




  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effectiveness of the addition of aripiprazole, an atypical antipsychotic, in the treatment of antipsychotic induced hyperprolactinaemia.